Multicenter, randomized, double-blind, placebo-controlled, study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn's Disease
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2012
At a glance
- Drugs Givinostat (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Italfarmaco
- 01 Feb 2012 Planned end date changed from 1 Jan 2010 to 1 Feb 2009 as reported by ClinicalTrials.gov.
- 16 Oct 2009 New trial record.